112results about How to "Maintain immunogenicity" patented technology

The invention relates to a method for preparing a small intestinal submucosa (SIS) soft tissue repair patch, and the soft tissue repair patch prepared by the method. The invention also relates to application of the soft tissue repair path to tissue repair.

The invention provides mutated, cytotoxic forms of Pseudomonas exotoxin A (PE) comprising a furin cleavage sequence conjugated or fused directly to residues 395-613 of PE or variants of that sequence. These minimal forms of PE are smaller than previous cytotoxic forms of PE, reduce non-specific toxicity, and reduce immunogenicity due to domain II or domain Ib of PE. The invention further provides nucleic acids encoding said PEs, chimeric molecules containing them, and methods of use thereof.

The invention discloses a mink distemper-canine parvovirus enteritis bivalent vaccine and its preparation method and use and belongs to the technical field of bioengineering. The mink distemper-canine parvovirus enteritis bivalent vaccine mainly comprises a mink distemper live vaccine, a mink canine parvovirus enteritis inactivated vaccine, a vaccine adjuvant and a protective agent. Aiming at one object, a ratio of the mink distemper live vaccine to the mink canine parvovirus enteritis inactivated vaccine is 1: 1. The invention also provides a preparation method and a use method of the mink distemper-canine parvovirus enteritis bivalent vaccine. The mink distemper-canine parvovirus enteritis bivalent vaccine is safe, has high efficiency, can save labor and can reduce a culture cost.

The invention discloses a recombinant bacillus displaying GCRV VP7 proteins on the surface of bacillus subtilis GC5 and a preparation method. The preparation method comprises the following steps: (1) obtaining a present epidemic strain type-II GCRV VP7 nucleotide sequence; (2) separating wide bacillus from the body of a grass carp, determining the wide bacillus to be bacillus subtilis, and naming the wide bacillus as Bacillus subtilis GC5, CCTCC NO: M2014654; (3) constructing a fusion expression recombinant integrated carrier, wherein a vp7 sequence in recombinant plasmids is the nucleotide sequence shown in SEQ ID No. 1; (4) preparing and authenticating recombinant bacillus subtilis, CCTCC NO: M2014655; (5) inducing and authenticating the recombinant bacillus displaying VP7 on the surface. The generation rate of spores is up to 100%, and the recombinant bacillus is simple and convenient to produce, low in cost, and capable of being used as a feed additive; the recombinant bacillus has an intestinal customization capacity, as well as is beneficial to regulating the intestinal bacterial colony balances of animals, improving the body immunocompetence of the animals, and enhancing the nutrition metabolism functions of the animals. The spores are high in stress resistance and easy for large-scale production, as well as solve the problem of instability of GCRV VP7 proteins used as immunizing antigens in extreme environments.

The invention relates to an acinetobacter baumannii A1S-1610 protein, a carrier, engineering bacteria, a composition or a kit which comprises the acinetobacter baumannii 1 A1S-1610 protein, and a preparation method and application of the acinetobacter baumannii 1 A1S-1610 protein, the acinetobacter baumannii 1 A1S-1610 protein is never used in the field of recombinant subunit vaccines, the acinetobacter baumannii 1 A1S-1610 protein can effectively stimulate the body to cause a protective immune response so as to resist acinetobacter baumannii lethal infection. The present invention also discloses a method for preparation of the recombinant protein by construction of an expression vector of the recombinant protein, and transformation of host bacteria, and use of the recombinant protein in the preparation of an acinetobacter baumannii resistant subunit vaccine and a related detection kit. The protective antigen composition A1S_1610 protein is expressed by use genetic engineering technology to clone, and the A1S_1610 protein is high in expression amount, easy to separate and purify, efficient and safe, and the genetic engineering recombinant subunit vaccine has good acinetobacter baumannii infection resistant immune protection effect.

The invention provides a preparation method of a triple inactivated vaccine for pigs. The method determines an antigen composition with excellent immunization effects by selection of the antigen. The prepared polyvalent vaccine has outstanding immunization effects. The prepared vaccine contains a PCP immunization protective antigen exotoxin (Aps), has cross immunization protection effects better than those of a whole cell inactivated vaccine, greatly reduces side reaction, and can simultaneously prevent haemophilus parasuis, swine streptococcosis and actinobacillus pleuropneumonia by combined immunization with inactivated haemophilus parasuis and streptococcus suis. Compared with haemophilus parasuis and streptococcus suis inactivated vaccines sold on the market, the triple inactivated vaccine has the same corresponding pathogen immune protection force. Compared with the actinobacillus pleuropneumonia inactivated vaccine sold on the market, the triple inactivated vaccine has a cross immunization protecting force on diseased pigs with different serotypes and realizes multiple protection purposes.

The invention provides a subunit vaccine for preventing novel coronavirus infection based on a bur protein S1 region of novel coronavirus and belongs to the field of vaccines. The subunit vaccine comprises a bur protein S1 region antigen of the novel coronavirus and an adjuvant and is used for preventing the novel coronavirus through subcutaneous or intramuscular injection for two or three times.According to the subunit vaccine provided by the invention, potential ADE risk caused by taking a full-length S protein as a novel coronavirus vaccine can be avoided, immunogenicity of RBD can also bereserved without introducing other viral antigens, and an antibody generated after immunization is sufficient to neutralize the novel coronavirus.

The invention relates to an African swine fever virus recombinant protein containing an intramolecular adjuvant, an expression vector and application, and belongs to the field of biotechnology pharmacy. The recombinant protein is formed by fusing African swine fever virus p30 and mp54 (modified p54) and an outer membrane protein I of pseudomonas aeruginosa. The recombinant protein has a general formula of OprI-(Linker)n-p30- (Linker)n-mp54, wherein a Linker sequence of a connecting peptide is selected from GGGGS or GGSGG, and is preferably GGGGS; and n is 1, 2, 3 or 4, and is preferably 3. Experiments prove that the recombinant protein can significantly promote maturation and differentiation of dendritic cells and secretion of cytokines. A vaccine immune animal prepared from the recombinant protein can stimulate an organism to generate a high-level neutralizing antibody and a cellular immune response, and can be used for preparation of an African swine fever virus diagnostic reagent and a preventive or therapeutic drug.

The invention relates to a clostridium perfringens Beta toxin recombination subunit vaccine and a production method thereof. The prepared clostridium perfringens Beta toxin recombination subunit vaccine is produced by using a recombination clostridium perfringens Beta toxin protein which is processed by codon optimization and contains 4 amino acid mutations, namely integrity and spatial conformation of a natural toxin protein are reserved in the greatest degree, so immunogenicity of the natural toxin protein is kept, and a biological potential safety hazard caused by the single amino acid mutation is avoided. The vaccine further has the advantages of simple preparation process, low immunizing dose, good vaccine efficacy and the like. Compared with a current commercial clostridium perfringens natural toxin inactivated vaccine in China, a bio-safety risk in a vaccine production process is greatly reduced. The vaccine is a perfect candidate vaccine for updating a current C-type clostridium perfringens toxin vaccine in China. In addition, while a mixed vaccine is prepared by the vaccine with other antigens, the mixed vaccine can be prepared without increasing a using dose of the mixedvaccine.

The invention discloses a desorption agent for desorbing an antigen in an aluminum salt adsorption type vaccine and an antigen content detection method. The desorption agent is a sodium citrate solution and comprises a nonionic surfactant which stabilizes protein conformation and increases detection specificity. The desorption agent for desorbing an antigen in an aluminum salt adsorption type vaccine can well desorb, meanwhile, a virus antigen structure is not affected or almost not affected, and the immunogenicity of the virus antigen structure is completely kept.

A method for preserving an aluminium-salt adjuvant during freezing or drying comprising freezing or drying an aqueous suspension or solution comprising: (a) an aluminium salt adjuvant; (b) a compound of formula (I) or a physiologically acceptable salt or ester thereof or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (c) optionally, one or more sugars.

The invention discloses a recombinant protein of active segment IsdB2 of decision protein IsdB on the surface of methicillin-resistant staphylococcus aureus iron ion, wherein the amino acid sequence of the recombinant protein is SEQ ID No: 3 or the sequence which has the same or similar function as the SEQ ID No: 3 obtained by adding or deleting a plurality of amino acids at the amino terminal and/or the carboxyl terminal of the SEQ ID No: 3. The invention further discloses a method for preparing the recombinant protein by building the expression vector of the recombinant protein and transforming the host bacteria, and the use of the recombinant protein in the aspect of preparing the subunit vaccine and the related assay kits resisting the methicillin-resistant staphylococcus aureus. By adopting the gene engineering technology, in the invention, the truncated protective antigens component IsdB2 is expressed by cloning through the protein expressing, thereby being high in expression index, convenient to separate and purify, and high-efficiency and safe. Due to the gene engineering, the recombinant polyvaccine has good immune protective effect on resisting the MRSA (methicillin-resistant staphylococcus aureus) infection.

The invention relates to the field of genetic engineering, and discloses PAL recombination protein of acinetobacter baumannii and a coding gene and application of the PAL recombination protein. The PAL recombination protein is (a) recombination protein as shown in SEQID NO:1 or SEQID NO:3; and (b) protein which is obtained by substituting, deleting and adding one or more amino acids for the aminoacid sequence as shown in SEQ ID NO:1 or SEQID NO:3, and has the same function as the recombination protein as shown in SEQID NO:1 or SEQID NO:3 and derived from (a) or protein which is prepared by connecting labels to the terminal of amino terminal and/or carboxyl terminal of the SEQID NO:1 or the SEQID NO:3 and shown in the amino acid sequence. The recombination protein is high in expression level, convenient to separate and purify, and high in efficacy and safe, can directly cooperate with an adjuvant for preparing a subunit vaccine and a relevant detection product, for resisting infectionof the acinetobacter baumannii.

The invention relates to the antitumor technical field, in particular to a novel tumor vaccine preparation method. Tumor cell lysis buffer subjected to treatment with hypochlorous acid is mixed with an immune activation agent to form a novel tumor vaccine. The method includes steps: 1) after fresh tumor tissues are obtained, performing primary tumor cell culture to obtain primary tumor cells; 2) subjecting the primary tumor cells obtained in the step 1) and culture solution to treatment with hypochlorous acid, collecting mixed solution obtained after cell treatment with hypochlorous acid to obtain required lysis buffer and apoptotic tumor cell debris mixture; 3) centrifuging the mixed solution obtained in the step 2), and repeatedly concentrating and purifying to obtain concentrated solution containing cell lysis buffer; 4) performing radiation inactivation on the cell lysis buffer purified and concentrated in the step 3). Problems of low immunogenicity, inaccuracy and low immunoreaction activation efficiency of common tumor antigen vaccines can be solved.

The invention discloses recombinant bacteria obtained from brucella 104M with Omp25 gene knockout for a vaccine strain and an application. The recombinant bacteria are obtained for reducing and/or inhibiting protein activity of Omp25 in brucella 104M. For the recombinant bacteria, reduction and/or inhibition of protein activity of Omp25 in brucella 104M refer/refers to inhibition or silencing of expression of an Omp25 protein coding gene in brucella 104M. Experiments prove that the recombinant bacteria are obtained by knocking out virulence gene Omp25 from brucella 104M, and delta Omp25 as a brucella attenuated vaccine candidate for human is screened out by means of research in virulence and immunogenicity of the recombinant bacteria.

The invention relates to an A1S-1462 recombinant protein and a preparation method and application thereof. The recombinant protein comprises A1S-1462 mature peptide, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO. 3. The recombinant protein is high in expression amount, easy to separate and purify, efficient and safe, can be directly used with an adjuvant, and is used for the preparation of an acinetobacter baumannii infection resistant subunit vaccine and a related detection kit. Confirmed by animal experiments, the genetic engineering recombinant subunit vaccine has good acinetobacter baumannii infection resistant immune protection effect, lays a foundation for the further study on combined vaccines and multicomponent fusion vaccines, and plays an important role for development and application of prevention and control vaccines and diagnostic kits.